Later-life IGF1R inhibition to preserve healthspan
PrimaryReGENE-associated research proposes that orally administered small-molecule inhibitors of the insulin-like growth factor 1 receptor (IGF1R) can modify aging-related functional decline and improve healthspan. The evolutionary rationale invokes antagonistic pleiotropy in IGF-1 signaling: its effects depend on life stage, providing a basis for testing receptor inhibition beginning in middle age. The testable prediction is that later-life IGF1R inhibition preserves cognition, metabolic and cardiovascular function, and physical resilience, potentially improving survival. In the supplied mouse study, PPP and NVP-ADW742 improved several functional measures, with some benefits differing by sex. NVP-ADW742 produced a squarer survival curve interpreted as 93 additional days of healthspan, but overall survival did not differ significantly between treatment groups. Toxicity and potential drug liabilities limit the therapeutic interpretation; human healthspan or lifespan benefits remain unestablished.
Popperian evaluation
Life-stage-dependent IGF-1 effects provide a credible basis for testing inhibition beginning in middle age. Antagonistic pleiotropy alone does not establish that receptor inhibition will preserve function, or identify an exposure that balances benefits against toxicity.
Supporting evidence: Treatment beginning at 13 months preserved short-term memory in male and female C57BL/6 mice with both compounds.; Reported benefits across glucose tolerance, cardiovascular measures, frailty and grip strength support biological plausibility, although several depended on sex.
Counter evidence: The supplied evidence does not establish that IGF1R inhibition caused the benefits through the proposed aging mechanism.; PPP-associated gastrointestinal bleeding and predicted NVP-ADW742 liabilities leave the therapeutic window uncertain.; Translation of the mouse benefits to humans remains an unsupported assumption.
The theory accommodates several functional benefits, but the supplied experiment does little to distinguish slowed aging from separate physiological drug effects. It also lacks a developed explanation for the sex-specific pattern. The evolutionary rationale motivates the intervention more clearly than it explains the results.
Supporting evidence: Two compounds produced overlapping functional benefits, which is consistent with a shared mechanism.; Benefits across multiple functional domains fit the prediction that later-life intervention can preserve healthspan.
Counter evidence: The supplied account does not report experiments that separate IGF1R-mediated effects from off-target effects.; Lower blood pressure and pulse rate alone do not establish preserved cardiovascular function or slower aging.; The reported 93 additional days of healthspan derive from survival-curve shape; the supplied account does not establish 93 additional days of measured preserved function.; Overall survival did not differ significantly between groups, leaving the survival prediction unsupported.
The theory specifies an intervention, a life stage and measurable functional outcomes. A trial with confirmed target inhibition, predefined endpoints and sufficient precision could reject a specified benefit. Its broad wording leaves room to select favorable outcomes unless effect thresholds and failure criteria are fixed before testing.
Supporting evidence: The mouse study operationalized treatment through diet beginning at 13 months, with 25 males and 25 females per treatment.; Memory, glucose tolerance, blood pressure, frailty, grip strength and survival provide observable tests of the predictions.; The reported absence of a statistically significant survival difference supplies an unfavorable result for one explicit prediction.
Counter evidence: The theory specifies no minimum benefit, required combination of outcomes or acceptable toxicity threshold.; A nonsignificant survival result alone cannot establish the absence of a survival effect without information about precision and power.; Testing treatment only from 13 months does not directly test the proposed dependence on starting age.
Reasoning tree
Public endorsements
Suvorov is a listed author of ReGENE's bioRxiv preprint, “Small-molecule IGF1R inhibitors extend healthspan in a mouse model.” Authorship publicly supports the paper's central claim that IGF1R inhibitors can improve healthspan measures in mice. It does not establish human benefit.
Evidence publication IDs: 48c3ffdb-e1ec-41df-8ac6-e95e6f901153
Eyermann is listed as an author on the ReGENE-associated bioRxiv preprint testing small-molecule IGF1R inhibitors in mice. Coauthorship publicly supports the research hypothesis, while leaving human benefit unestablished.
Basarab is listed as a coauthor of the bioRxiv preprint "Small-molecule IGF1R inhibitors extend healthspan in a mouse model," which directly advances the theory that IGF1R inhibition can improve later-life functional outcomes in mice.
The supplied evidence identifies Mila Getmansky Sherman’s prior role in quantitative research at Deutsche Asset Management. It contains no public statement from her about ReGENE, IGF1R inhibition, aging, healthspan, or the theory’s evidence.
The supplied evidence contains no statement from SENS Co about IGF1R inhibition, ReGENE, or later-life healthspan intervention. The records are unrelated or a parked-domain snapshot.